Drug

ApicHope's Oral Small‑Molecule GLP‑1R Agonist APH04935 Wins FDA IND Approval – Once‑Daily Pill Targets Obesity in Competitive Weight Loss Market
ApicHope PharmaceuticalClinical trial approval / initiation

ApicHope’s Oral Small‑Molecule GLP‑1R Agonist APH04935 Wins FDA IND Approval – Once‑Daily Pill Targets Obesity in Competitive Weight Loss Market

ApicHope Pharmaceutical Group Co., Ltd. (SHE: 300723) announced that its wholly‑owned subsidiary, Guangzhou ApicHope Pharmaceutical Co., Ltd., has received Investigational New Drug (IND) approval from the U.S. Food and Drug…

Xinhua Pharmaceutical Secures NMPA Registration for Generic Sacubitril/Valsartan Tablets – Entering China's RMB 7.8 Billion Heart Failure Market

Xinhua Pharmaceutical Secures NMPA Registration for Generic Sacubitril/Valsartan Tablets – Entering China’s RMB 7.8 Billion Heart Failure Market

SSY Group Secures NMPA Approval for Nimodipine Oral Solution – Bulk Drug‑to‑Formulation Vertical Integration Strengthens Cerebrovascular Portfolio

SSY Group Secures NMPA Approval for Nimodipine Oral Solution – Bulk Drug‑to‑Formulation Vertical Integration Strengthens Cerebrovascular Portfolio

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Clinical trial approval / initiationGeneScience Pharmaceutical

Changchun GeneScience Receives NMPA Approval for Firsekibart Phase III Trial in Gout Flare Prevention During Urate-Lowering Therapy

Merus' Bizengri Becomes First FDA-Approved Therapy for NRG1 Fusion-Positive Cholangiocarcinoma
CancerMerus

Merus’ Bizengri Becomes First FDA-Approved Therapy for NRG1 Fusion-Positive Cholangiocarcinoma

ADC / XDCCancer

Zai Lab Secures FDA Fast Track Designation for DLL3-Targeting ADC Zocilurtatug Pelitecan in Extrapulmonary NEC

Clinical trial filingsHKG: 6938

Ribo Life Science Files EMA Application for Vortosiran Phase IIb Study in Venous Thromboembolism Prevention

Show More